Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer

Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:

“We’re finally seeing decades of cancer research converging on new effective treatment options for our patients with hormone receptor-positive breast cancer.

The CDK4/6 inhibitors abemaciclib and ribociclib have shown significant benefits in the adjuvant setting; the first new endocrine treatment, elacestrant, has been approved after 20 years without approvals in this field; the first AKT inhibitor, capivasertib, has entered the clinic; the novel ADCs trastuzumab deruxtecan and sacituzumab govitecan have been approved after demonstrating to improve survival over traditional chemotherapy, and; neoadjuvant immunotherapy with pembrolizumab or nivolumab has shown compelling results on pathologic tumor response, promising to enter the clinic soon.

For a recap and contextualization of these novel options, don’t miss our SABCS23 symposium on HR+ breast cancer, featuring Erika Hamilton, Komal Jhaveri, Hope Rugo and myself, and now available on YouTube.”

View the symposium on YouTube.
Source: Paolo Tarantino/LinkedIn